Schedule

November 4 - 6, 2011
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD

Program Schedule

To view slides from a presenter click the icon next to the presentation title.

Friday, November 4
7:50 am - 8:00 am	President's Welcome Thomas F. Gajewski, MD, PhD - University of Chicago
8:00 am - 8:45 am	Richard V. Smalley, MD Memorial Lectureship Vaccines That Target Dendritic Cells Ralph M. Steinman, MD - The Rockefeller University Speaker :  TBD
8:45 am - 11:30 am	Plenary Session:  Biology & Application of Dendritic Cells Co-Chairs:    Nina Bhardwaj, MD, PhD - NYU Medical Center                      Viggo Van Tendeloo, PhD - Antwerp University Hospital Invited Speakers:     Nina Bhardwaj, MD, PhD - NYU Medical Center                      Robert Seder, MD - NIAID, NIH                      Viggo Van Tendeloo, PhD - Antwerp University Hospital
8:45 am - 9:15 am	Optimizing T Cell Immunity with Prime-Boost Immunization Using Viral and Protein/Adjuvant Based Vaccines Robert A. Seder, MD - NIAID, NIH
9:15 am - 9:30 am	Human Langerhans Dendritic Cells Stimulate Robust Cytolytic T-Cells Against Tumor Antigens, Including WT1, by an IL15-Dependent Mechanism Emanuela Romano, MD - University Hospital of Lausanne
9:30 am - 10:00 am	Dendritic Cell Vaccines for Leukemia in an Adjuvant Post-remission Setting Viggo Van Tendeloo, PhD - Antwerp University Hospital
10:00 am - 10:15 am	The Host STING Pathway is Critical for Innate Immune Sensing at a Growing Tumor and Bridging to an Adaptive Immune Response via IFN-beta Seng-Ryong Woo, PhD - University of Chicago
10:15 am - 10:45 am	Break
10:45 am - 11:00 am	Adenovirus-Engineered Human Dendritic Cell Vaccine Induces Natural Killer Cell Chemotaxis via CXCL8/IL-8 and CXCL10/IP-10 Chemokines Lazar Vujanovic, PhD - University of Pittsburgh
11:00 am - 11:30 am	Modulation of Dendritic Cell Function by the Tumor Microenvironment Nina Bhardwaj, MD, PhD - NYU School of Medicine
11:30 am - 12:00 pm	Plenary Session: Late Breaking Oral Abstracts Moderator:    Francesco Marincola, MD - National Institutes of Health
11:30 am - 11:45 am	Phase I Study of Intravenous Recombinant Human Interleukin-15 (RH IL-15) in Adults with Metastatic Malignant Melanoma and Renal Cell Carcinoma Kevin C. Conlon, MD, MS - National Cancer Institute, NIH
11:45 am - 12:00 pm	Reversal of Local Immune Evasion Mechanisms and Regression of Human Merkel Cell Carcinoma by Intralesional Injection of Interferon-Beta Kelly G. Paulson - University of Washington
12:00 pm - 1:30 pm	Lunch Break & Poster Viewing
12:30 pm - 1:30 pm	Odd Numbered Poster Presentations by Authors
1:30 pm - 3:00 pm	Concurrent Session I:  Immunology of Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT) Co-Chairs:     Malcolm A.S. Moore, D.Phil - Memorial Sloan-Kettering Cancer Center                       Jeffrey Schlom, PhD - National Cancer Institute, NIH Invited Speakers:     Malcolm A.S. Moore, D.Phil - Memorial Sloan-Kettering Cancer Center                      Claudia M. Palena, PhD - National Cancer Institute, NIH
1:30 pm - 2:00 pm	Cancer Testis (CT) Antigens Expressed in Ovarian Tumor-Initiating Cells Malcolm A.S. Moore, DPhil - Memorial Sloan-Kettering Cancer Center
2:00 pm - 2:30 pm	Immunotherapeutic Approaches to EMT and Cancer Stem Cells Claudia M. Palena, PhD - National Cancer Institute, NIH
2:30 pm - 2:45 pm	Immunological Targeting of Epithelial to Mesenchymal Transition as a Strategy to Prevent Breast Cancer Metastases Sandra Demaria, MD - New York University School of Medicine
2:45 pm - 3:00 pm	Potential for Immunotherapeutic Control of CSC-like Cells Through their Expression of FAS and DR5 Death Receptors Trina Stewart, PhD - Peter MacCallum Cancer Centre
1:30 pm - 3:00 pm	Concurrent Session II: Uncoupling Negative Regulation in the Tumor Microenvironment Co-Chairs:    Lieping Chen, MD, PhD - Yale University                      Hassane M. Zarour, MD - University of Pittsburgh Invited Speakers:     Lieping Chen, MD, PhD - Yale University                      Hassane M. Zarour, MD - University of Pittsburgh
1:30 pm - 2:00 pm	Immune Checkpoints in the Cancer Microenvironment Lieping Chen, MD, PhD - Yale Cancer Center, Yale School of Medicine, Immunobiology
2:00 pm - 2:15 pm	IL-12 Triggers an Inflammatory Gene Signature that Reverses Dysfunctional Antigen-presentation by Myeloid-Derived Cells Residing within Tumors Sid Kerkar, MD - National Cancer Institute, Center for Cancer Research, NIH
2:15 pm - 2:30 pm	Acute Myeloid Leukemia Promotes Immune Evasion through Induction of Antigen-Specific T Cell Deletion Justin P. Kline, MD - University of Chicago
2:30 pm - 3:00 pm	Targeting Multiple Inhibitory Pathways to Reverse Melanoma-induced T Cell Dysfunction Hassane M. Zarour, MD - University of Pittsburgh
3:00 pm - 3:15 pm	Break
3:15 pm - 5:15 pm	Plenary Session:  Genetically Engineered Receptors and Adoptive Cell Therapies Co-Chairs:     Carl H. June, MD - University of Pennsylvania                       Dolores J. Schendel, PhD - Helmholz Zentrum Muenchen -                                                                  German Research Center for Environmental Health Invited Speakers:     Laurence J.N. Cooper, MD, PhD - MD Anderson Cancer Center                      Carl H. June, MD - University of Pennsylvania                      Dolores J. Schendel, PhD - Helmholz Zentrum Muenchen -                                                                  German Research Center for Environmental Health
3:15 pm - 3:45 pm	Genetically Engineered Receptors in Adoptive Cell Therapies Laurence J.N. Cooper, MD, PhD - MD Anderson Cancer Center
3:45 pm - 4:15 pm	Selection of Allo-Restricted Peptide-Specific TCRs for Adoptive T Cell Therapy Dolores J. Schendel, PhD - Helmholtz Zentrum Muenchen - German Research Center for Environmental Health Institute of Molecular Immunology
4:15 pm - 4:30 pm	Differential Gene Expression Associated with Immune Down Regulation in TCR Gene-engineered T Cells Administered to Patients Daniel Abate-Daga, PhD - National Cancer Institute
4:30 pm - 4:45 pm	Active STAT5 Promotes Long-Lived Cytotoxic CD8 T Cells that Induce Regression of Autochthonous Mouse Melanoma Gregory Verdeil, PhD - Centre d’Immunologie de Marseille-Luminy, CIML
4:45 pm - 5:15 pm	Engineered T Cell Therapies for Hematologic Malignancies Carl H. June, MD - University of Pennsylvania
5:15 pm - 5:45 pm	Plenary Session: Cancer Immunotherapy Trials Network (CITN) Update Speaker:       Mary L. (Nora) Disis, MD - Co-Principal Investigator, Cancer Immunotherapy Trials                                                             Network (CITN); University of Washington
5:45 pm - 6:15 pm	SITC Membership Business Meeting
Immediately Following the Business Meeting 8:00 pm	Poster & Networking Reception
6:15 pm - 7:00 pm	Odd Numbered Poster Presentations by Authors
7:15 pm - 8:00 pm	Even Numbered Poster Presentations by Authors
Saturday, November 5
8:00 am - 8:45 am	Keynote Address: Innate Immune Recognition of Nucleic Acids Katherine Fitzgerald, PhD - University of Massachusetts Medical School
8:45 am - 11:30 am	Plenary Session:  Characterization of Inflammatory Infiltrates in Human Cancers Co-Chairs:     George Coukos, MD, PhD - University of Pennsylvania Medical Center                       Wolf-Hervé Fridman, MD, PhD - INSERM Invited Speakers:      Vincenzo Bronte, MD - Verona University - Immunology Section                       George Coukos, MD, PhD - University of Pennsylvania Medical Center                       Wolf-Hervé Fridman, MD, PhD - INSERM
8:45 am - 9:15 am	Chemokine Regulation of T Cell Response in Ovarian Cancer George Coukos, MD, PhD - University of Pennsylvania Medical Center
9:15 am - 9:30 am	DC Vaccination Concurrently Reduces Treg and Enhances Activated CTL in Tumor Biopsies from Immunoresponsive Patients with Advanced Melanoma Massimo Guidoboni, MD - Immunology & Somatic Cell Therapy Lab
9:30 am - 10:00 am	Contrasted Prognostic Impact of Tumor Infiltration by Various Subsets of Immune Cells Wolf Hervé Fridman, MD, PhD - INSERM
10:00 am - 10:15 am	Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Breast Cancer Skin Metastases Sylvia Adams, MD - NYU Cancer Institute
10:15 am - 10:45 am	Break
10:45 am - 11:00 am	Serial Imaging of Inflammation and Therapeutic Response with Clinically Translational 19F MRI Amy K. Wesa, PhD - Celsense, Inc
11:00 am - 11:30 am	Post-translational Chemokine Modification Prevents Intratumoral Infiltration of Antigen-specific T Cells Vincenzo Bronte, MD - Verona University - Immunology Section
11:30 am - 12:00 pm	Plenary Session: Late Breaking Abstracts Moderator:   Francisco Marincola, MD - National Institutes of Health
11:30 am - 11:45 am	Frequency of Strong Antibody Responses Following Combination Immunotherapy Correlates with Increased PSA Doubling Time in Men with Androgen-Independent Prostate Cancer Sachin Puri, PhD - Earle A. Chiles Research Institute
11:45 am - 12:00 pm	IDO1 Activity Correlates with Hepatocyte Growth Factor Levels and Immune System Impairment in Multiple Myeloma Sergio Rutella, MD, PhD - IRCCS Bambino Gesù Children’s Hospital
12:00 pm - 1:30 pm	Lunch Break & Poster Viewing
12:30 pm - 1:30 pm	Even Numbered Poster Presentations by Authors
1:30 pm - 3:00 pm	Concurrent Session I:  State of the Art Animal Models and Veterinary Applications for Cancer and Immunology Co-Chairs:     Thomas Blankenstein, PhD - Max-Delbruck Center for Molecular Medicine                       Jedd D. Wolchok, MD, PhD - Memorial Sloan-Kettering Cancer Center Invited Speakers:      Thomas Blankenstein, PhD - Max-Delbruck Center for Molecular Medicine                        Taha Merghoub, PhD - Memorial Sloan-Kettering Cancer Center
1:30 pm - 2:00 pm	The Immune Response to Sporadic Antigenic Cancer Thomas Blankenstein, PhD - Max-Delbruck Center for Molecular Medicine
2:00 pm - 2:15 pm	NOD/scid IL2Rgnull Mice: A Model for Human Dendritic Cell-Based Immunotherapies Stefani Spranger - Helmholtz Zentrum München
2:15 pm - 2:30 pm	Intracranial Administration of Human Activated NK Cells in a Xenogeneic Model of Orthotopic Glioblastoma William J. Murphy, PhD - University of California-Davis
2:30 pm - 3:00 pm	Overcoming Vaccine Resistance in a Model of Spontaneous Melanoma Taha Merghoub, PhD - Memorial Sloan-Kettering Cancer Center
1:30 pm - 3:00 pm	Concurrent Session II:  High Throughput Technologies for Immune Monitoring Co-Chairs:     Philipp Beckhove, MD - German Cancer Research Center                       Sacha Gnjatic, PhD - Ludwig Institute for Cancer Research Invited Speakers:     Philipp Beckhove, MD - German Cancer Research Center                      Sacha Gnjatic, PhD - Ludwig Institute for Cancer Research
1:30 pm - 2:00 pm	Tumour Reactive T Cell Responses as Biomarkers: Correlation to Tumour Cell Biology and Treatment Response Philipp Beckhove, MD - German Cancer Research Center
2:00 pm - 2:15 pm	Immunological Correlates of Long-Term Survival in Melanoma Patients Graham Pawelec, PhD - University of Tuebingen
2:15 pm - 2:30 pm	New Biomarkers for PROSTVAC-VF Discovered Using High-Throughput Glycan Microarrays Christopher Campbell, MD, PhD - National Cancer Institute
2:30 pm - 3:00 pm	Seromics: Measuring Antigen-Specific Serum Antibody Responses During Anticancer Immunotherapies for Correlation with Clinical Events Sacha Gnjatic, PhD - Ludwig Institute for Cancer Research
3:00 pm - 3:30 pm	Break
3:30 pm - 4:50 pm	Presidential Abstract Session Chair:             Thomas F. Gajewski, MD, PhD - University of Chicago
3:30 pm - 3:50 pm	Immunotransplant for Mantle Cell Lymphoma: a Phase I/II Study Demonstrating Amplification of Tumor-Reactive T Cells Joshua Brody, MD - Stanford University Medical Center
3:50 pm - 4:10 pm	IRF5 Gene Polymorphism in Melanoma Lorenzo Uccellini, PhD - National Institutes of Health, CC, DTM
4:10 pm - 4:30 pm	Improved in Vivo Persistence of CD19-Specific T Cells Expressing a Membrane-Bound Form of IL-15 Lenka Hurton - M.D. Anderson Cancer Center
4:30 pm - 4:50 pm	Dysfunctional Tumor-Infiltrating T Cells Express the Anergy-Associated Molecules Lymphocyte-Activation Gene 3 (LAG3) and Class-I-MHC Restricted T Cell Associated Molecules (CRTAM) Yan Zheng, PhD - University of Chicago
4:50 pm - 5:20 pm	Clinical Immunotherapy Guidelines Update Speaker:         Howard L. Kaufman, MD - Rush University Medical Center
5:20 pm - 5:35 pm	National Cancer Institute, NIH Update Speaker:         William Merritt, PhD - National Cancer Institute
5:35 pm - 5:50 pm	FDA Update on Regulatory Issues Related to Cancer Immunotherapy Speaker:         Raj K. Puri, MD, PhD - Food and Drug Administration, CBER
5:50 pm - 6:15 pm	Award Presentations
6:15 pm - 8:00 pm	Presidential Reception with Exhibits/Poster Viewing and Presentations
After 8:00 pm/ Presidential Reception	Performance by the band The Checkpoints
Sunday, November 6
8:00 am - 10:15 am	Plenary Session:  Prostate Cancer as a Learning Model Co-Chairs:   Charles G. Drake, MD, PhD - Johns Hopkins University                     James L. Gulley, MD, PhD - National Cancer Institute Invited Speakers:    Charles G. Drake, MD, PhD - Johns Hopkins University                     James L. Gulley, MD, PhD - National Cancer Institute                     Douglas G. McNeel, MD, PhD - University of Wisconsin
8:00 am - 8:30 am	Immune Checkpoint Blockade in Prostate and Other Cancers Charles G. Drake, MD, PhD - Johns Hopkins University
8:30 am - 9:00 am	Repetitive DNA Vaccination Elicits PAP Antigen-Specific T Cell Immune Responses in Patients with Castrate-Resistant Prostate Cancer Douglas G. McNeel, MD, PhD - University of Wisconsin
9:00 am - 9:15 am	Intradermal Immunization with a Novel mRNA Based Vaccination Technology Induces Strong T and B Cell Responses in Phase I/ IIa Trials in Non-Small Cell Lung Cancer (NSCLC) and Prostate Carcinoma (PCA) Birgit Scheel, PhD - CureVac GmbH
9:15 am - 9:30 am	Lymphoid and Myeloid Biomarkers for Clinical Outcome of Ipilimumab and Prostate GVAX Treatment: Tumor-related CTLA-4 Expression by CD4+ T Cells as a Dominant Predictor of Survival Tanja D. De Gruijl, PhD - VU University Medical Center
9:30 am - 9:45 am	Comprehensive Characterization of Polyomavirus BK Large Tumor Antigen Epitopes to Promote the Expansion of Effector T Lymphocytes in Prostate Cancer Patients Maurizio Provenzano, MD, PhD - University Hospital of Zurich
9:45 am - 10:15 am	Combining Vaccines with Other Therapeutics: A Strategy to Accelerate Proof of Concept Studies James L. Gulley, MD, PhD, FACP - National Cancer Institute
10:15 am	Annual Meeting Adjourns
10:15 am - 12:00 pm	Hot Topic Symposium: Targeting the Next Generation of Inhibitory Pathways

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.